DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: RE34672
|Title:||Pharmaceutical composition containing a stable modification of torasemide|
|Abstract:||The present invention provides a process for the preparation of cystalline torasemide in the pure modification I (monoclinic, space group P2.sub.1 /c, melting point 162.degree. C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169.degree. C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete. The present invention also provides pharmaceutical compositions containing torasemide of modification I.|
|Inventor(s):||Topfmeier; Fritz (Heidelberg, DE), Lettenbauer; Gustav (Lampertheim, DE)|
|Assignee:||Boehringer Mannheim GmbH (Mannheim, DE)|
1. A diuretic pharmaceutical composition comprising an effective amount of rapidly dissolving .Iadd.stable .Iaddend.crystalline torasemide of pure modification I (monoclinic,
space group P2.sub.1 /c, melting point .Badd..[.169.degree. C..]..Baddend. .Iadd.of about 159.degree. C. to about 161.5.degree. C., in prism form.Iaddend.) substantially free of crystalline torasemide of modification II (monoclinic, space group P2/n,
melting point .Badd..[.162.degree. C..]..Baddend. .Iadd.of about 157.5.degree. C. to about 160.degree. C., in leaflet form.Iaddend.) and a pharmacologically acceptable carrier, said torasemide of modification I .Iadd.being storage stable in tablet
form and .Iaddend.having solubility characteristics such that at least 60% is dissolved in water after 15 minutes, and at least 80% is dissolved in water after 30 minutes.
2. The composition of claim 1 comprising, by weight, approximately:
100 parts of the torasemide of modification I and, as the carrier,
20 parts lactose monohydrate,
77 parts maize starch,
2parts silicon dioxide and,
1 part magnesium stearate.
3. The composition of claim 1 comprising, by weight, approximately:
25parts of the torasemide of modification I and, as the carrier,
605 parts lactose monohydrate,
160 parts maize starch,
6 parts silicon dioxide and
4 parts magnesium stearate. .Iadd.
4. A method of producing a diuretic effect in a patient, said method comprising orally administering to the patient at least one storage-stable table consisting essentially of torasemide of pure modification I (monoclinic, space group P2.sub.1 /c, melting point of about 159.degree. to about 161.5.degree. C., in prism form) and being substantially free of crystalline torasemide of modification II (monoclinic, space group P2/n, melting point of about 157.5.degree. C. to about 160.degree. C., in leaflet form). .Iaddend.
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.